KRAS and lung carcinoma: To date, direct inhibition of K-Ras has not yet been successful in clinical therapy, whereas inhibitors targeting ERK, such as binimetinib and trametinib, are approved to treat melanoma (Roskoski, 2020) and are under clinical trial for treatment of lung cancer (Heigener et al., 2015).